The customer service I received was top-notch. The...
The customer service I received was top-notch. The company was able to address all of my concerns and resolve any issues I had in a timely manner. I appreciate their professionalism and would recommend their services to others.
I recently used Geron for the first time, and I mu...
I recently used Geron for the first time, and I must say I was impressed. Their website was easy to use, and their customer service was outstanding. I had a few questions and they were answered promptly. I will definitely be using their services again in the future.
Geron is a reliable company that offers great serv...
Geron is a reliable company that offers great services. I am very satisfied with their website and the customer service I received. The staff was helpful and friendly. Keep up the good work!
I love Geron! 😊 Their website, geron.com, is user-...
I love Geron! 😊 Their website, geron.com, is user-friendly and visually appealing. The service I received was excellent, and the staff was always friendly and helpful. I'm very satisfied with my experience and will definitely be a returning customer. 👍
I had an amazing experience with Geron. The websit...
I had an amazing experience with Geron. The website is easy to navigate and the staff is very friendly. I received prompt and efficient customer service. I highly recommend their services!
I had a great experience with Geron. Their website...
I had a great experience with Geron. Their website, geron.com, is easy to navigate and has all the information I needed. The customer service was excellent, and they were able to answer all of my questions quickly and efficiently. I would highly recommend Geron to others.
关于Geron
Geron:彻底改变血液髓系恶性肿瘤的治疗
Geron 是一家临床阶段的生物制药公司,一直处于开发血液骨髓恶性肿瘤创新疗法的前沿。该公司的主要重点是开发 imetelstat,这是一种端粒酶抑制剂,已在临床试验中显示出可喜的结果。
血液髓系恶性肿瘤是一组影响骨髓中造血细胞的癌症。这些包括骨髓增生异常综合征 (MDS)、急性髓性白血病 (AML) 和慢性粒单核细胞白血病 (CMML) 等疾病。这些疾病可能难以治疗,因此迫切需要新的疗法。
Imetelstat 通过抑制端粒酶起作用,端粒酶是一种在癌细胞生长和存活中起关键作用的酶。通过靶向端粒酶,imetelstat 有可能减缓甚至停止癌细胞的生长。对于几乎没有可用治疗选择的血液髓系恶性肿瘤患者来说,这使它成为一个令人兴奋的前景。
Geron 对开发 imetelstat 的承诺导致了多项成功的临床试验。在一项研究中,与接受安慰剂的患者相比,接受 imetelstat 的 MDS 患者的总生存期明显更长。另一项试验在复发或难治性 AML 患者中显示出有希望的结果。
这些试验的成功促使 Geron 继续研究 imetelstat 并探索其在其他类型癌症中的潜在用途。
除了在 imetelstat 上的工作外,Geron 还有其他几个专注于开发癌症和其他疾病新疗法的项目。其中包括专注于小分子抑制剂和基于 RNA 的疗法的项目。
总的来说,Geron 是一家创新的生物制药公司,致力于通过对 imetlelstat 等新疗法的开创性研究来改善血液骨髓恶性肿瘤患者的预后。 Geron 致力于推进科学和改善患者护理,准备在抗击癌症和其他疾病方面做出重大贡献。
业务透明度
- 未验证公司信息
- 向他们的客户询问评论
- 没有回复负面评论